Inferring tumour purity and stromal and immune cell admixture from expression data
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Infiltrating stromal and immune cells form the major fraction of normal cells in tumour tissue and not only perturb the tumour signal in molecular studies but also have an important role in cancer biology. Here we describe ‘Estimation of STromal and Immune cells in MAlignant Tumours using Expression data’ (ESTIMATE)—a method that uses gene expression signatures to infer the fraction of stromal and immune cells in tumour samples. ESTIMATE scores correlate with DNA copy number-based tumour purity across samples from 11 different tumour types, profiled on Agilent, Affymetrix platforms or based on RNA sequencing and available through The Cancer Genome Atlas. The prediction accuracy is further corroborated using 3,809 transcriptional profiles available elsewhere in the public domain. The ESTIMATE method allows consideration of tumour-associated normal cells in genomic and transcriptomic studies. An R-library is available on https://sourceforge.net/projects/estimateproject/ . Tumour biopsies contain contaminating normal cells and these can influence the analysis of tumour samples. In this study, Yoshihara et al.develop an algorithm based on gene expression profiles from The Cancer Genome Atlas to estimate the number of contaminating normal cells in tumour samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“this result is not merely a reflection of the extent of immune infiltration, as indicated by the lack of correlation between the γδ T cell signature score and ESTIMATE (Yoshihara et al., 2013) immune signature score for individual patients”
From Commensal Microbiota Promote Lung Cancer Development via γδ T Cells (2019) · cites this paper as Yoshihara et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 2×
“We devised two gene signatures: (1) a ‘stromal signature’ that was designed to capture the presence of stroma in tumour tissue, and (2) an ‘immune signature’ that aimed to represent the infiltration of immune cells in tumour tissue (Supplementary Data 1).”
MethodRSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Cited by
Items 101–200 of 1,021
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Liu, Z., Li, M., Jiang, Z., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.011 · Cited by 275
Chen, Y.-P., Wang, Y.-Q., Lv, J.-W., Li, Y.-Q., Chua, M. L. K., Le, Q.-T., Lee, N., Colevas, A. D., Seiwert, T., Hayes, D. N., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy470 · Cited by 275
“We confirmed that one of the NMFidentified clusters was linked to inflammatory markers and immune cells, which has been corroborated by an observed high immune enrichment score as reported previously [8, 10] (supplementary Figure S2A, available at Annals of Oncology online).”
ResultGenova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 260
“number of computational algorithms have been developed for the prediction of non-cancer cell infiltration (Table 1) (75, 79, 82, 85, 86, 88, 89).”
BackgroundZhang, Z., Zeng, X., Wu, Y., Liu, Y., Zhang, X., & Song, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925618 · Cited by 275
“Immune Profile Analysis The immune score and stromal score of each sample in TCGALIHC cohort was calculated by the “estimate” package in R (33).”
MethodKim, K.-T., Lee, H. W., Lee, H.-O., Kim, S. C., Seo, Y. J., Chung, W., Eum, H. H., Nam, D.-H., Kim, J., Joo, K. M., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0692-3 · Cited by 268
“validated genomic analyses utilizing WES [26, 27] and expression profiles [28] indicated that human cancer cells were highly enriched (~100 %) in the PDX cells (Fig.”
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms
Hu, H., Piotrowska, Z., Hare, P. J., Chen, H., Mulvey, H. E., Mayfield, A., Noeen, S., Kattermann, K., Greenberg, M., Williams, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.003 · Cited by 265
Cancer transcriptome profiling at the juncture of clinical translation
Cieślik, M., & Chinnaiyan, A. M. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.96 · Cited by 269
Hakimi, A. A., Voss, M. H., Kuo, F., Sanchez, A., Liu, M., Nixon, B. G., Vuong, L., Ostrovnaya, I., Chen, Y.-B., Reuter, V., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0957 · Cited by 258
“Utilizing ESTIMATE immune score (18), total immune infiltration was similar among IMDC risk groups (Kruskal– Wallis test, P = 0.”
MethodInfluentialImmune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
Gil Del Alcazar, C. R., Huh, S. J., Ekram, M. B., Trinh, A., Liu, L. L., Beca, F., Zi, X., Kwak, M., Bergholtz, H., Su, Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0222 · Cited by 247
“Associations in copy-number gain were estimated using a linear model taking into account parameters including PAM50 subtype, neoantigen load (53), overall copynumber aberration, immune content (54), and patient age.”
MethodMapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer
Li, R., Ferdinand, J. R., Loudon, K. W., Bowyer, G. S., Laidlaw, S., Muyas, F., Mamanova, L., Neves, J. B., Bolt, L., Fasouli, E. S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.001 · Cited by 244
“ccRCC is a cancer type with heavy infiltration of immune cells.(9,10) Harnessing adaptive immunity through immune checkpoint blockade (ICB) therapy is effective in improving the survival of patients,(11,12) highlighting the importance of the immunemicroenvironment of ccRCC.”
Computational deconvolution of transcriptomics data from mixed cell populations
Avila Cobos, F., Vandesompele, J., Mestdagh, P., & De Preter, K. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty019 · Cited by 248
Wu, J., Li, L., Zhang, H., Zhao, Y., Zhang, H., Wu, S., & Xu, B. (2021) · Oncogene · doi:10.1038/s41388-021-01853-y · Cited by 254
Gong, J., Li, Y., Liu, C.-J., Xiang, Y., Li, C., Ye, Y., Zhang, Z., Hawke, D. H., Park, P. K., Diao, L., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.070 · Cited by 249
Jiménez-Sánchez, A., Cybulska, P., Mager, K. L., Koplev, S., Cast, O., Couturier, D.-L., Memon, D., Selenica, P., Nikolovski, I., Mazaheri, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0630-5 · Cited by 243
Immuno-genomic landscape of osteosarcoma
Wu, C.-C., Beird, H. C., Andrew Livingston, J., Advani, S., Mitra, A., Cao, S., Reuben, A., Ingram, D., Wang, W.-L., Ju, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14646-w · Cited by 251
“Characteristic n (%) Median age at diagnosis in years (range) 27 (5-81) Gender Male 29 (60) Female 19 (40) Race White 30 (63) Hispanic 10 (21) Black 5 (10) Asian 3 (6) Disease stage at presentation Localized 37 (77) Metastatic 11 (23) Histologic subtype Osteoblastic 14 (29) Fibroblastic 9 (19) Chondroblastic 6 (13) Ex…”
BackgroundSelf-citationChan, C. S., Laddha, S. V., Lewis, P. W., Koletsky, M. S., Robzyk, K., Da Silva, E., Torres, P. J., Untch, B. R., Li, J., Bose, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06498-2 · Cited by 234
Abelin, J. G., Harjanto, D., Malloy, M., Suri, P., Colson, T., Goulding, S. P., Creech, A. L., Serrano, L. R., Nasir, G., Nasrullah, Y., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.012 · Cited by 240
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., Hakansson, L. G., Hanks, B. A., Karanikas, V., Khleif, S. N., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0243-4 · Cited by 228
“New computational methods, however, such as ESTIMATE [82] and CIBERSORT [83, 84] that utilize cell-specific gene expression signatures to infer relative fractions of immune and stromal cell populations from whole tumor gene expression profiles are making progress toward this limitation.”
Zimmerman, M. W., Liu, Y., He, S., Durbin, A. D., Abraham, B. J., Easton, J., Shao, Y., Xu, B., Zhu, S., Zhang, X., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0993 · Cited by 232
“24 (Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) to evaluate tumor purity in each tumor (43).”
Zeng, D., Wu, J., Luo, H., Li, Y., Xiao, J., Peng, J., Ye, Z., Zhou, R., Yu, Y., Wang, G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002467 · Cited by 236
“28 Immun-eScore, Stromalscore, and tumor purity were assessed computationally in RNA-seq data using the ESTIMATE algorithm 29 that uses gene expression signatures to infer the fraction of stromal and immune cells in tumor samples.”
MethodLiu, Q., Zhang, J., Guo, C., Wang, M., Wang, C., Yan, Y., Sun, L., Wang, D., Zhang, L., Yu, H., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.004 · Cited by 207
Zhang, X., Shi, M., Chen, T., & Zhang, B. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.08.030 · Cited by 232
“ESTIMATE evaluated the immune and stromal contents (immune and stromal score) for each HNSC sample.(20) The hierarchical agglomerative clustering of HNSC was executed as per the ICI pattern of each sample.”
BackgroundMethodChong, W., Shang, L., Liu, J., Fang, Z., Du, F., Wu, H., Liu, Y., Wang, Z., Chen, Y., Jia, S., et al. (2021) · Theranostics · doi:10.7150/thno.52717 · Cited by 229
“The Estimation of Stromal and Immune Cells in Malignant Tumors using Expression Data (ESTIMATE) algorithm [46], which takes advantage of the unique properties of the transcriptional profiles to infer the tumor cellularity as well as the tumor purity.”
Ma, S., Sun, B., Duan, S., Han, J., Barr, T., Zhang, J., Bissonnette, M. B., Kortylewski, M., He, C., Chen, J., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01398-6 · Cited by 225
Cellular architecture of human brain metastases
Gonzalez, H., Mei, W., Robles, I., Hagerling, C., Allen, B. M., Hauge Okholm, T. L., Nanjaraj, A., Verbeek, T., Kalavacherla, S., van Gogh, M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.043 · Cited by 219
Deng, J., Li, J., Sarde, A., Lines, J. L., Lee, Y.-C., Qian, D. C., Pechenick, D. A., Manivanh, R., Le Mercier, I., Lowrey, C. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0507 · Cited by 224
Comprehensive Benchmarking and Integration of Tumor Microenvironment Cell Estimation Methods
Jiménez-Sánchez, A., Cast, O., & Miller, M. L. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3560 · Cited by 210
Tumour evolution and microenvironment interactions in 2D and 3D space
Mo, C.-K., Liu, J., Chen, S., Storrs, E., Targino da Costa, A. L. N., Houston, A., Wendl, M. C., Jayasinghe, R. G., Iglesia, M. D., Ma, C., et al. (2024) · Nature · doi:10.1038/s41586-024-08087-4 · Cited by 184
Zhang, H., Christensen, C. L., Dries, R., Oser, M. G., Deng, J., Diskin, B., Li, F., Pan, Y., Zhang, X., Yin, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.11.003 · Cited by 220
Geffen, Y., Anand, S., Akiyama, Y., Yaron, T. M., Song, Y., Johnson, J. L., Govindan, A., Babur, Ö., Li, Y., Huntsman, E., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.013 · Cited by 209
“20.0) Johnson et al.146 https://bioconductor.org/packages/release/ bioc/html/sva.html ESTIMATE Yoshihara et al.72 https://bioinformatics.mdanderson.org/ public-software/estimate/ fGSEA Subramanian et al.147 http://bioconductor.org/packages/release/ bioc/html/fgsea.html GSVA Hänzelmann et al.148 https://www.bioconduct…”
InfluentialSelf-citationThe molecular landscape of glioma in patients with Neurofibromatosis 1
D’Angelo, F., Ceccarelli, M., Tala, Garofano, L., Zhang, J., Frattini, V., Caruso, F. P., Lewis, G., Alfaro, K. D., Bauchet, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0263-8 · Cited by 213
Wu, M., Li, X., Zhang, T., Liu, Z., & Zhao, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00996 · Cited by 217
Intratumoral Heterogeneity of the Epigenome
Mazor, T., Pankov, A., Song, J. S., & Costello, J. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.009 · Cited by 214
“Such an approach has already been developed for expression datasets (Yoshihara et al., 2013).”
BackgroundLu, H., Arshad, M., Thornton, A., Avesani, G., Cunnea, P., Curry, E., Kanavati, F., Liang, J., Nixon, K., Williams, S. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08718-9 · Cited by 212
Dalin, M. G., Desrichard, A., Katabi, N., Makarov, V., Walsh, L. A., Lee, K.-W., Wang, Q., Armenia, J., West, L., Dogan, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0637 · Cited by 214
“The average estimated tumor purity was 68% (range, 52%–93%), which is higher than reported for most tumor types, including breast cancer (20).”
BackgroundMethodOptical Forces: From Fundamental to Biological Applications
Xin, H., Li, Y., Liu, Y., Zhang, Y., Xiao, Y., & Li, B. (2020) · Advanced Materials · doi:10.1002/adma.202001994 · Cited by 212
Bidkhori, G., Benfeitas, R., Klevstig, M., Zhang, C., Nielsen, J., Uhlen, M., Boren, J., & Mardinoglu, A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807305115 · Cited by 211
“05; Dataset S3), up-regulation of genes associated with previously identified immune signatures (37), and metastasization such as HIF1α, IL1, TNFα, NFκB, and TGFβ (Dataset S3).”
BackgroundImmune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Panda, A., Mehnert, J. M., Hirshfield, K. M., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L., Stein, M. N., Poplin, E., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx213 · Cited by 208
Abou Khouzam, R., Brodaczewska, K., Filipiak, A., Zeinelabdin, N. A., Buart, S., Szczylik, C., Kieda, C., & Chouaib, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613114 · Cited by 198
Cell-type deconvolution in epigenome-wide association studies: a review and recommendations
Teschendorff, A. E., & Zheng, S. C. (2017) · Epigenomics · doi:10.2217/epi-2016-0153 · Cited by 206
Gabitova-Cornell, L., Surumbayeva, A., Peri, S., Franco-Barraza, J., Restifo, D., Weitz, N., Ogier, C., Goldman, A. R., Hartman, T. R., Francescone, R., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.015 · Cited by 203
“org/) Subsequent analyses were limited to 76 cases with the PDAC fraction inferred to be >30% by the ESTIMATE method (Yoshihara et al., 2013) as described in (TCGA.”
MethodApplications of Immunogenomics to Cancer
Liu, X. S., & Mardis, E. R. (2017) · Cell · doi:10.1016/j.cell.2017.01.014 · Cited by 205
Shah, N., Wang, P., Wongvipat, J., Karthaus, W. R., Abida, W., Armenia, J., Rockowitz, S., Drier, Y., Bernstein, B. E., Long, H. W., et al. (2017) · eLife · doi:10.7554/elife.27861 · Cited by 201
Jin, H., Zhang, C., Zwahlen, M., von Feilitzen, K., Karlsson, M., Shi, M., Yuan, M., Song, X., Li, X., Yang, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41132-w · Cited by 170
Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing
Euskirchen, P., Bielle, F., Labreche, K., Kloosterman, W. P., Rosenberg, S., Daniau, M., Schmitt, C., Masliah-Planchon, J., Bourdeaut, F., Dehais, C., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1743-5 · Cited by 196
“One GBM sample that was not classifiable had low tumor purity when estimated from matched transcriptomic profiles using the ESTIMATE algorithm [41] (Fig.”
MethodImmunoregulatory functions of VISTA
Nowak, E. C., Lines, J. L., Varn, F. S., Deng, J., Sarde, A., Mabaera, R., Kuta, A., Le Mercier, I., Cheng, C., & Noelle, R. J. (2017) · Immunological Reviews · doi:10.1111/imr.12525 · Cited by 197
Kim, K.-T., Lee, H. W., Lee, H.-O., Song, H. J., Jeong, D. E., Shin, S., Kim, H., Shin, Y., Nam, D.-H., Jeong, B. C., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-0945-9 · Cited by 198
“sources: stromal signature, extracted from the ESTIMATE package [62]; ccRCC signature, taken from Jones et al.”
MethodSelf-citationLiu, Z., Zhao, Y., Kong, P., Liu, Y., Huang, J., Xu, E., Wei, W., Li, G., Cheng, X., Xue, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.004 · Cited by 184
Metabolism‐associated molecular classification of hepatocellular carcinoma
Yang, C., Huang, X., Liu, Z., Qin, W., & Wang, C. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12639 · Cited by 189
“In addition, immune scores and stromal scores were calculated by applying the ESTIMATE algorithm, which can reflect the enrichment of stromal and immune cell gene signatures (Yoshihara et al., 2013).”
MethodCillo, A. R., Cardello, C., Shan, F., Karapetyan, L., Kunning, S., Sander, C., Rush, E., Karunamurthy, A., Massa, R. C., Rohatgi, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.036 · Cited by 180
Shao, W., Yang, Z., Fu, Y., Zheng, L., Liu, F., Chai, L., & Jia, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.676485 · Cited by 190
Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities
Wang, W., Kandimalla, R., Huang, H., Zhu, L., Li, Y., Gao, F., Goel, A., & Wang, X. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.002 · Cited by 187
Yi, L., Wu, G., Guo, L., Zou, X., & Huang, P. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.06.001 · Cited by 193
A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability
Morel, A.-P., Ginestier, C., Pommier, R. M., Cabaud, O., Ruiz, E., Wicinski, J., Devouassoux-Shisheboran, M., Combaret, V., Finetti, P., Chassot, C., et al. (2017) · Nature Medicine · doi:10.1038/nm.4323 · Cited by 186
Re-definition of claudin-low as a breast cancer phenotype
Fougner, C., Bergholtz, H., Norum, J. H., & Sørlie, T. (2020) · Nature Communications · doi:10.1038/s41467-020-15574-5 · Cited by 177
Zheng, S. C., Webster, A. P., Dong, D., Feber, A., Graham, D. G., Sullivan, R., Jevons, S., Lovat, L. B., Beck, S., Widschwendter, M., et al. (2018) · Epigenomics · doi:10.2217/epi-2018-0037 · Cited by 187
Xu, W.-H., Xu, Y., Wang, J., Wan, F.-N., Wang, H.-K., Cao, D.-L., Shi, G.-H., Qu, Y.-Y., Zhang, H.-L., & Ye, D.-W. (2019) · Aging · doi:10.18632/aging.102233 · Cited by 190
“calculated specific molecular biomarker expression in immune and stromal cells, and thus generated an ESTIMATE algorithm with immune/stromal/ESTIMATE scores to predict the TME [9].”
MethodLiu, Z., Guo, C., Dang, Q., Wang, L., Liu, L., Weng, S., Xu, H., Lu, T., Sun, Z., & Han, X. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103750 · Cited by 181
Marzouka, N.-A.-D., Eriksson, P., Rovira, C., Liedberg, F., Sjödahl, G., & Höglund, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-22126-x · Cited by 181
Ju, M., Bi, J., Wei, Q., Jiang, L., Guan, Q., Zhang, M., Song, X., Chen, T., Fan, J., Li, X., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa345 · Cited by 185
“These results were completely consistent with our previous findings, which indicated that the NLRP3 inflammasome score can be seemed as a good indicator for prognosis and survival in SKCM. NLRP3 inflammasome score significantly correlate with TILs in various cancers in 15 cancer types To explore the correlation betwee…”
BackgroundMethodInfluentialMolecular classification and diagnostics of upper urinary tract urothelial carcinoma
Fujii, Y., Sato, Y., Suzuki, H., Kakiuchi, N., Yoshizato, T., Lenis, A. T., Maekawa, S., Yokoyama, A., Takeuchi, Y., Inoue, Y., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.008 · Cited by 180
Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer
Xu, Q., Chen, S., Hu, Y., & Huang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.711433 · Cited by 180
Castagnoli, L., Cancila, V., Cordoba-Romero, S. L., Faraci, S., Talarico, G., Belmonte, B., Iorio, M. V., Milani, M., Volpari, T., Chiodoni, C., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0700-2 · Cited by 184
Sanchez, A., Furberg, H., Kuo, F., Vuong, L., Ged, Y., Patil, S., Ostrovnaya, I., Petruzella, S., Reising, A., Patel, P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30797-1 · Cited by 181
Panda, A., de Cubas, A. A., Stein, M., Riedlinger, G., Kra, J., Mayer, T., Smith, C. C., Vincent, B. G., Serody, J. S., Beckermann, K. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121522 · Cited by 181
BEST: a web application for comprehensive biomarker exploration on large-scale data in solid tumors
Liu, Z., Liu, L., Weng, S., Xu, H., Xing, Z., Ren, Y., Ge, X., Wang, L., Guo, C., Li, L., et al. (2023) · Journal of Big Data · doi:10.1186/s40537-023-00844-y · Cited by 162
“4A), including CIBERSORT [21], CIBERSORT ABS [21], EPIC [22], ESTIMATE [23], MCP-counter [24], Quantiseq [25], TIMER [26], and xCell [27].”
MethodLightbody, G., Haberland, V., Browne, F., Taggart, L., Zheng, H., Parkes, E., & Blayney, J. K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby051 · Cited by 173
A landscape of metabolic variation across tumor types
Reznik, E., Luna, A., Aksoy, B. A., Liu, E. M., La, K., Ostrovnaya, I., Creighton, C. J., Hakimi, A. A., & Sander, C. (2018) · Cell Systems · doi:10.1016/j.cels.2017.12.014 · Cited by 172
Applications of single-cell and bulk RNA sequencing in onco-immunology
Kuksin, M., Morel, D., Aglave, M., Danlos, F., Marabelle, A., Zinovyev, A. Y., Gautheret, D., & Verlingue, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.005 · Cited by 208
Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment
Jiang, Z., Liu, Z., Li, M., Chen, C., & Wang, X. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.068 · Cited by 171
“ESTIMATE yields the immune score for each tumor sample that quantifies the immune activity (immune infiltration level) in that tumor sample based on its gene expression profiles.”
BackgroundMethodInfluentialMurai, H., Kodama, T., Maesaka, K., Tange, S., Motooka, D., Suzuki, Y., Shigematsu, Y., Inamura, K., Mise, Y., Saiura, A., et al. (2023) · Hepatology · doi:10.1002/hep.32573 · Cited by 168
Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine
Ogino, S., Nowak, J. A., Hamada, T., Phipps, A. I., Peters, U., Milner Jr, D. A., Giovannucci, E. L., Nishihara, R., Giannakis, M., Garrett, W. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315537 · Cited by 169
Rajbhandari, P., Lopez, G., Capdevila, C., Salvatori, B., Yu, J., Rodriguez-Barrueco, R., Martinez, D., Yarmarkovich, M., Weichert-Leahey, N., Abraham, B. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0861 · Cited by 170
“To further disentangle tumor specific signatures from those of tumor infiltrating compartments in 11qLOH and MES subtypes, we used the ESTIMATE algorithm, which allows inferring both the stromal and immune fractions in each sample (29) (Supplementary Figure S2 A–D).”
Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors
Leruste, A., Tosello, J., Ramos, R. N., Tauziède-Espariat, A., Brohard, S., Han, Z.-Y., Beccaria, K., Andrianteranagna, M., Caudana, P., Nikolic, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.008 · Cited by 161
Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
Cerezo-Wallis, D., Contreras-Alcalde, M., Troulé, K., Catena, X., Mucientes, C., Calvo, T. G., Cañón, E., Tejedo, C., Pennacchi, P. C., Hogan, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1073-3 · Cited by 162
Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression
Khan, F., Lin, Y., Ali, H. A., Pang, L., Dunterman, M., Hsu, W.-H., Frenis, K., Rowe, R. G., Wainwright, D. A., McCortney, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46193-z · Cited by 179
“The metabolism signature and immune score in The Cancer Genome Atlas (TCGA) glioblastoma tumors have been de fi ned based on gene expression data to infer the levels of tumor metabolism 30 and immune cell populations 31 , respectively.”
Wang, T., Lu, R., Kapur, P., Jaiswal, B. S., Hannan, R., Zhang, Z., Pedrosa, I., Luke, J. J., Zhang, H., Goldstein, L. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1246 · Cited by 168
“We profiled the expression of genes from the ESTIMATE signature (2), a signature made up of stromal and immune genes.”
MethodZhang, H., Li, R., Cao, Y., Gu, Y., Lin, C., Liu, X., Lv, K., He, X., Fang, H., Jin, K., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000004037 · Cited by 168
“The signature scores, calculated by the geomean of FPKM expression of related genes, were used to indicate the relative abundance of IL-10þ TAMs in TCGA samples.(21)”
MethodACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma
Tong, L., Li, J., Li, Q., Wang, X., Medikonda, R., Zhao, T., Li, T., Ma, H., Yi, L., Liu, P., et al. (2020) · Theranostics · doi:10.7150/thno.41498 · Cited by 162
“The relationship between STAT3 mRNA and the infiltrating nontumor cells in glioma was characterized using the ESTIMATE algorithm developed by Yoshihara et al.[37].”
MethodLeveraging big data to transform target selection and drug discovery
Chen, B., & Butte, A. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.318 · Cited by 160
“35 Second, large technical and biological variation of samples exists.”
BackgroundConnolly, R. M., Li, H., Jankowitz, R. C., Zhang, Z., Rudek, M. A., Jeter, S. C., Slater, S. A., Powers, P., Wolff, A. C., Fetting, J. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1729 · Cited by 162
“Tumor purity for primary tumors was estimated from gene expression using the Estimate-Project method (26).”
MethodSelf-citationYu, K., Chen, B., Aran, D., Charalel, J., Yau, C., Wolf, D. M., van ‘t Veer, L. J., Butte, A. J., Goldstein, T., & Sirota, M. (2019) · Nature Communications · doi:10.1038/s41467-019-11415-2 · Cited by 156
Chen, D., Liu, J., Zang, L., Xiao, T., Zhang, X., Li, Z., Zhu, H., Gao, W., & Yu, X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66913 · Cited by 158
“In addition, Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) algorithm was implemented to predict the presence of infiltrating stromal/immune cells based on the expression profiles of HCC patients [19].”
MethodXu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163
“27 The ESTIMATE score can differentiate the tumor and stomal components but cannot distinguish speci fi c immune cell types. xCell is another ssGSEA-based method that obtains gene sets to characterize distinct cell types from multiple RNA-seq and microarray-based data sources, increasing the…”
MethodSong, C., Piva, M., Sun, L., Hong, A., Moriceau, G., Kong, X., Zhang, H., Lomeli, S., Qian, J., Yu, C. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0401 · Cited by 158
“We used the ESTIMATE algorithm (37) to calculate the extent of immune infiltration of the baseline and On-Tx tumors based on gene expression data.”
MethodZhang, C., Zheng, J.-H., Lin, Z.-H., Lv, H.-Y., Ye, Z.-M., Chen, Y.-P., & Zhang, X.-Y. (2020) · Aging · doi:10.18632/aging.102824 · Cited by 160
“Then, immune score was calculated by applying the ESTIMATE algorithm to the matrix data [11].”
BackgroundMethodSystematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment
Varn, F. S., Wang, Y., Mullins, D. W., Fiering, S., & Cheng, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2490 · Cited by 153
Tang, Y., Li, C., Zhang, Y.-J., & Wu, Z.-H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.55552 · Cited by 159
“Immunity analysis and gene expression At the same time, the CIBERSORT [16, 17], ESTIMATE [18], MCPcounter [19], single-sample gene set enrichment analysis (ssGSEA) [20] and TIMER [21] algorithms were compared to assess cellular components or cell immune responses between high risk and low risk group based on ferroptos…”
MethodJiang, Y., Wang, J., Sun, M., Zuo, D., Wang, H., Shen, J., Jiang, W., Mu, H., Ma, X., Yin, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34689-5 · Cited by 142
Mitochondrial complex I promotes kidney cancer metastasis
Bezwada, D., Perelli, L., Lesner, N. P., Cai, L., Brooks, B., Wu, Z., Vu, H., Sondhi, V., Cassidy, D. L., Kasitinon, S. Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07812-3 · Cited by 166
“The ESTIMATE R package 57 was used to derive stromal and immune scores and a tumour purity ESTIMATE score from RNA sequencing data.”
Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer
Zeng, D., Ye, Z., Wu, J., Zhou, R., Fan, X., Wang, G., Huang, Y., Wu, J., Sun, H., Wang, M., et al. (2020) · Theranostics · doi:10.7150/thno.46176 · Cited by 159
“Consistently with previous research [13], FGFR pathway mutations were not statistically correlated with anti-PD-L1 response, but were markedly enriched in desert-immune subtype and high tumor purity [72].”
ResultMolecular subtyping of cancer: current status and moving toward clinical applications
Zhao, L., Lee, V. H. F., Ng, M. K., Yan, H., & Bijlsma, M. F. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby026 · Cited by 151
Kalaora, S., Lee, J. S., Barnea, E., Levy, R., Greenberg, P., Alon, M., Yagel, G., Eli, G. B., Oren, R., Peri, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14639-9 · Cited by 170
Zheng, H., Liu, H., Ge, Y., & Wang, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02252-9 · Cited by 173
Starrett, G. J., Luengas, E. M., McCann, J. L., Ebrahimi, D., Temiz, N. A., Love, R. P., Feng, Y., Adolph, M. B., Chelico, L., Law, E. K., et al. (2016) · Nature Communications · doi:10.1038/ncomms12918 · Cited by 169
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0240-9 · Cited by 154
Cheng, F., Zhao, J., & Zhao, Z. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv068 · Cited by 161
“described ESTIMATE, a computational method to infer the fraction of stromal and immune cells in tumor samples using gene expression signatures [118].”
MethodWang, X., Xie, T., Luo, J., Zhou, Z., Yu, X., & Guo, X. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01516-0 · Cited by 163
“with the tumor microenvironment and immunophenotype To test the hypothesis that the radiomics score could reflect the heterogeneity of the tumor microenvironment, the ESTIMATE method was used to infer tumor purity of the high- and low-score groups [23].”
MethodMao, W., Cai, Y., Chen, D., Jiang, G., Xu, Y., Chen, R., Wang, F., Wang, X., Zheng, M., Zhao, X., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.161940 · Cited by 145
“In addition, statin acts as tumor-suppressive roles in multiple cancers (22, 24).”
BackgroundMethodBAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Shrestha, R., Nabavi, N., Lin, Y.-Y., Mo, F., Anderson, S., Volik, S., Adomat, H. H., Lin, D., Xue, H., Dong, X., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0620-3 · Cited by 147
Metadata
- Authors
- Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., Carter, S. L., Getz, G., Stemke-Hale, K., Mills, G. B., & Verhaak, R. G. W.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Southern California (US)
- Memorial Sloan Kettering Cancer Center (US)
- Broad Institute (US)
- Corresponding author
- Verhaak, Roel G.W.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-10-11
- Volume
- 4
- Issue
- 1
- Pages
- 2612-2612
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3826632
- OpenAlex
- W2130430382
- Cited by
- 9,778
- References
- 63
- Citations by year
- 2026: 694 · 2025: 1176 · 2024: 1602 · 2023: 1755 · 2022: 1988 · 2021: 1316 · 2020: 683 · 2019: 223 · 2018: 121 · 2017: 93 · 2016: 53 · 2015: 39 · 2014: 20 · 2013: 2
- FWCI
- 17.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (P50CA098258, U24CA143882, CA143883, U24CA143883, P30CA008748, P30CA016672)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- tumor purity, tumor stroma, tumor-infiltrating immune cells, gene expression signatures, tumor microenvironment, DNA copy number, cancer transcriptomics
- MeSH terms
- Algorithms, Cell Separation, Female, Humans, Leukocytes, Neoplasms, Research Design, Sensitivity and Specificity, Software, Gene Library, Genome, Human, Stromal Cells, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, DNA Copy Number Variations, High-Throughput Nucleotide Sequencing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.